Icelanders, whose unusually low genetic variability makes them ideal for
studies on the origin of diseases, have agreed to reveal the secrets of their
genes to pharmaceuticals company Hoffmann-La Roche. The deal, worth $200
million, gives the company and its partner—deCode Genetics of
Reykjavik—exclusive rights to develop drugs from the genetic data of
Iceland’s population. In return, Icelanders will receive any resulting medicines
free.
More from New ÒÁÈ˾þÃ
Explore the latest news, articles and features
Mind
The relationship recession is even bigger for Gen Z than we thought
News
Technology
Killer robots are here – we must finally decide whether to accept them
Leader
Technology
Quantum computer quickly mines cryptocurrency while using less energy
News
Mind
How to sparkle in conversation with strangers
Comment
Popular articles
Trending New ÒÁÈ˾þà articles
1
Fully autonomous drones have killed human soldiers for the first time
2
Millions of fossil whale bones found in deep-ocean ‘necropolis’
3
Understanding anorexia’s grip on the brain could unlock new therapies
4
Weird and wonderful sea pen found on Mystery Ridge
5
Unpicking endometriosis reveals how it affects more than the pelvis
6
Why you need to future-proof your brain in middle age and how to start
7
Wolves seen hunting European bison in rare camera-trap recording
8
Have we finally worked out how Venus flytraps snap shut?
9
El Niño has started and the weather could get weird
10
How to sparkle in conversation with strangers
